Qupet 1% w/w10 gm

Qupet 1% w/w is an FDA-approved topical antibiotic indicated for the treatment of impetigo caused by susceptible isolates of Staphylococcus aureus (methicillin-susceptible strains) or Streptococcus pyogenes in adult and pediatric patients within the approved age range.

• Established/approved use: Topical treatment of impetigo (a superficial bacterial skin infection) due to S. aureus or S. pyogenes.
• Not established: Qupet 1% w/w is not indicated for infections of the eyes, mouth, or mucous membranes, for deep or systemic skin infections, or for infections caused by organisms other than the labeled pathogens.

There is no well-established off-label use for Qupet 1% w/w; it should be used strictly for its approved topical dermatologic indication.

Each gram of Ozenoxacin topical cream contains 10 mg (1% w/w) of ozenoxacin as the active ingredient, formulated in a cream base for external dermal application.

Qupet 1% w/w is a non-fluorinated quinolone antibacterial agent developed specifically for topical dermatologic use. Unlike traditional fluoroquinolones, Qupet 1% w/w lacks a fluorine atom at the core quinolone structure, a design feature intended to reduce the potential for cross-resistance with systemic fluoroquinolone antibiotics. It is formulated as a 1% topical cream for the treatment of impetigo.

Qupet 1% w/w belongs to the class of topical non-fluorinated quinolone antibacterial agents, used specifically for dermatologic (skin) infections.

Ozenoxacin exerts its antibacterial effect by inhibiting two essential bacterial enzymes involved in DNA replication: DNA gyrase (topoisomerase II) and topoisomerase IV. Inhibition of these enzymes prevents bacterial DNA supercoiling, replication, and cell division, resulting in bactericidal activity against susceptible organisms including Staphylococcus aureus and Streptococcus pyogenes.

Pharmacokinetics: Systemic absorption of Ozenoxacin following topical application is minimal to undetectable in clinical studies, which limits the potential for systemic adverse effects.

Qupet 1% w/w cream is for topical (external) skin use only. It is not for ophthalmic, oral, intravaginal, or intranasal use. Apply only to intact or lesioned skin areas as directed by the physician, avoiding mucous membranes.

No clinically significant drug-drug interactions have been well established for topical Qupet 1% w/w, owing to its minimal systemic absorption after dermal application.

• Other topical products: Concurrent use of other topical medications on the same skin area is not recommended unless directed by a physician, as this may affect absorption or local tolerability.

Always inform your physician or pharmacist about all other medicines (including topical products) you are using before starting Qupet 1% w/w.

Topical Qupet 1% w/w is generally well tolerated. Reported adverse effects are typically mild and local.

• Common: Application-site reactions such as erythema (redness), irritation, pruritus (itching), or a mild burning/stinging sensation at the site of application.
• Uncommon: Contact dermatitis, dryness, or exfoliation of the skin at the treated site.
• Rare: Hypersensitivity reactions (see Contraindications and Precautions).

If severe irritation, blistering, or signs of an allergic reaction occur, discontinue Qupet 1% w/w and consult a physician promptly.

Pregnancy: There are no adequate and well-controlled studies of Qupet 1% w/w in pregnant women. Because systemic absorption after topical application is minimal, systemic fetal exposure is expected to be low; however, Qupet 1% w/w should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Consult a physician before use.

Lactation: It is not known whether topically applied Qupet 1% w/w is excreted in human milk. Caution should be exercised when prescribing Qupet 1% w/w to a breastfeeding woman; avoid application to the breast/nipple area, and consult a physician before use.

Qupet 1% w/w is for external use only. The following precautions apply:

• Avoid contact with the eyes, mouth, lips, nostrils, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.
• Discontinue use and seek medical advice if signs of hypersensitivity, severe local irritation, or contact dermatitis develop.
• Complete the full prescribed 5-day course even if symptoms improve earlier, to ensure eradication of the infection and to minimize the risk of recurrence or antibacterial resistance.
• Qupet 1% w/w is not intended for the treatment of infections other than impetigo caused by the specified organisms; do not use for unrelated skin conditions without medical advice.
• Antibiotic stewardship: Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• If clinical signs of worsening infection, systemic symptoms (e.g., fever), or superinfection occur, seek medical attention promptly.

Topical Qupet 1% w/w has a low potential for overdose due to minimal systemic absorption. In the event of accidental ingestion or extensive/excessive application leading to concerning symptoms, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt unsupervised home treatment for suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Qupet 1% w/w is approved for use in pediatric patients 2 months of age and older for impetigo due to susceptible organisms; safety and efficacy in infants younger than 2 months have not been established.

Geriatric use: Clinical studies of Qupet 1% w/w included patients across a broad age range; no overall differences in safety or effectiveness have been observed between elderly and younger patients, but caution is advised given typically thinner or more fragile skin in this population.

Renal/hepatic impairment: No dose adjustment is established or considered necessary given the minimal systemic absorption of topically applied Qupet 1% w/w.

Pregnancy and lactation: See Pregnancy and Lactation section above.

The standard recommended duration of treatment with Qupet 1% w/w for impetigo is 5 consecutive days, applied twice daily. The full course should be completed even if lesions appear to resolve earlier, unless a physician advises otherwise.

Topical Antibacterial – Non-Fluorinated Quinolone

Ozenoxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, two enzymes essential for bacterial DNA replication, transcription, and repair. By blocking these enzymes, Ozenoxacin prevents bacterial cell division, leading to bactericidal activity against susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Its non-fluorinated chemical structure is designed to reduce cross-resistance potential with systemic fluoroquinolone antibiotics.

Qupet 1% w/w is indicated for the treatment of impetigo due to S. aureus or S. pyogenes in pediatric patients 2 months of age and older, using the same twice-daily application regimen for 5 days as in adults, applied to the affected area only. Safety and efficacy in infants below 2 months of age have not been established, and use in this age group is not recommended unless directed by a physician.